2013
Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
Delpech Y, Coutant C, Hsu L, Barranger E, Iwamoto T, Barcenas CH, Hortobagyi GN, Rouzier R, Esteva FJ, Pusztai L. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. British Journal Of Cancer 2013, 108: 285-291. PMID: 23299541, PMCID: PMC3566807, DOI: 10.1038/bjc.2012.557.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaBreast-conserving surgeryNeoadjuvant chemotherapyPure lobular carcinomaLobular carcinomaClinical benefitTumor sizeER-positive invasive ductal carcinomasLower pathological complete response rateResponse ratePathological complete response ratePathological response rateComplete response rateGood clinical responsePathological complete responseType of chemotherapyPositive surgical marginsSurgical resection marginsClinical responseNodal statusComplete responseResection marginsSurgical marginsDuctal carcinomaPositive margins
2012
Survival outcomes in HER2-positive invasive lobular breast carcinoma.
Barcenas C, Hess K, Delpech Y, Pusztai L, Hortobagyi G, Giordano S, Esteva F. Survival outcomes in HER2-positive invasive lobular breast carcinoma. Journal Of Clinical Oncology 2012, 30: 612-612. DOI: 10.1200/jco.2012.30.15_suppl.612.Peer-Reviewed Original ResearchInvasive lobular breast carcinomaDisease-free survivalER/PRInvasive ductal carcinomaLobular breast carcinomaSurvival outcomesOverall survivalBreast carcinomaCox proportional hazards regressionMD Anderson Cancer CenterProgesterone receptor statusRare clinical entityBreast cancer patientsProportional hazards regressionNumber of patientsAnderson Cancer CenterMedian followBetter OSMedian ageReceptor statusClinical entityDuctal carcinomaHazards regressionCancer CenterLobular carcinoma
2007
Primary systemic chemotherapy of invasive lobular carcinoma of the breast
Katz A, Saad ED, Porter P, Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. The Lancet Oncology 2007, 8: 55-62. PMID: 17196511, DOI: 10.1016/s1470-2045(06)71011-7.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaInvasive ductal carcinomaLobular carcinomaSystemic chemotherapyDuctal carcinomaAdjuvant systemic chemotherapyPrimary systemic chemotherapyUse of chemotherapyFrequent histological typeProspective clinical trialsDistinct clinical entityAdjuvant chemotherapyRandomised trialsHistological typeClinical entityBreast diseaseClinical trialsBreast cancerEstrogen receptorChemotherapyInsufficient evidencePrevention strategiesCarcinomaBest treatmentLow grade
2006
Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)?
Katz A, Saad E, Pusztai L. Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)? Journal Of Clinical Oncology 2006, 24: 10541-10541. DOI: 10.1200/jco.2006.24.18_suppl.10541.Peer-Reviewed Original ResearchInvasive lobular carcinomaHormone therapyILC patientsRandomized trialsInvasive ductal carcinomaNA chemotherapyBreast cancerNA therapyPCR rateRetrospective seriesEstrogen receptorPhase III randomized trialsPathologic response rateRole of chemotherapyIndependent predictive factorsOngoing randomized trialsEarly breast cancerFuture randomized trialsInvasive breast cancerDistinct clinical behaviorPotential therapeutic implicationsAdjuvant trialsCT regimensPossible overtreatmentIDC patients